Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25262919 | 0.84 | ENPP2 (0.39) | ADAMTS5MGLLENPP2ATXN2 | |
| SCHEMBL25261087 | 0.80 | ADAMTS5 (0.39) | TRPV4ADAMTS5PKMENPP2ATXN2 | |
| SCHEMBL25290123 | 0.79 | EPHX2 (0.40) | CACNA1BTRPV4ADAMTS5PKMMGLL | |
| SCHEMBL25253376 | 0.77 | CACNA1B (0.48) | CACNA1BTRPV4PLA2G1BPKMATG4B | |
| SCHEMBL25296988 | 0.76 | PRCP (0.38) | ADAMTS5CYP2C9 | |
| SCHEMBL30409788 | 0.75 | MGLL (0.44) | CACNA1BPKMMGLL | |
| SCHEMBL25146103 | 0.75 | CACNA1B (0.41) | CACNA1BTRPV4PLA2G1BPKMATG4B | |
| SCHEMBL25295986 | 0.73 | TEAD1 (0.38) | CYP2C9 | |
| SCHEMBL25296539 | 0.73 | F13A1 (0.50) | CACNA1B | |
| SCHEMBL31308002 | 0.72 | EPHX2 (0.42) | CACNA1BTRPV4MGLLCNR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | claimed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | claimed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | claimed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | CACNA1B 2069/4885TRPV4 4192/4885CA2 3696/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | CACNA1B 2069/4885TRPV4 4192/4885CA2 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.